Rimac joins Cognoa to provide financial and strategic leadership, bringing over 30 years of broad operating and finance experience within the pharmaceutical, medical device, biotechnology, and drug delivery industries
This article was originally published on AIMed in Feature: Real Life, 08/12/2021 Cognoa’s device is the first FDA-authorized diagnosis aid designed to help primary care physicians diagnose autism in young children with the goal of enabling earlier interventions In June, the FDA granted a De Novo classification request to Canvas Dx, a machine learning-driven autism diagnostic solution, developed by pediatric behavioral health company…
Cognoa’s AI-driven device is the first FDA-authorized diagnosis aid designed to help primary care physicians diagnose autism in young children with the goal of shortening time-to-diagnosis and enabling initiation of earlier interventions (Palo Alto, Calif. – June 2nd, 2021) – Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, today announced…
By David Happel This article was originally published in Autism Parenting Magazine, Issue 118. Nearly 80 years after psychiatrist Leo Kanner became the first physician to use the term “autism”, children and families with autism still face critical gaps and unnecessary delays on their way to a diagnosis. Rather than diagnosing children themselves, pediatricians typically refer children with suspected developmental delays to specialists—setting…
Written By Jason Hartman As a part of our series about business leaders who are shaking things up in their industry, I had the pleasure of interviewing David Happel. David Happel is the President and CEO of Cognoa, the leading digital diagnostics and therapeutics company developing FDA cleared pediatric behavioral health solutions. Prior to joining Cognoa, Happel served as President,…